bimatoprost (lumigan) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Bimatoprost (marketed in the US, Canada and Europe by Allergan, under the trade name Lumigan) ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a prostaglandin analogue that works by increasing the outflow of aqueous fluid from the eyes. It binds to the prostanoid FP receptor. It selectively mimics the effects of naturally occurring substances, prostamides. Bimatoprost is believed to lower intraocular pressure (IOP) in humans by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Elevated IOP presents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss. Bimatoprost is the major circulating species in the blood once it reaches the systemic circulation following ocular dosing. Bimatoprost then undergoes oxidation, N-deethylation and glucuronidation to form a diverse variety of metabolites. In human blood, bimatoprost resides mainly in the plasma. Approximately 12% of bimatoprost remains unbound in human plasma.   NCATS

Chemistry

  • SMILES: CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC2=CC=CC=C2
  • InChIKey: AQOKCDNYWBIDND-FTOWTWDKSA-N
  • Mol. Mass: 415.5656
  • ALogP: 3.15
  • ChEMBL Molecule:
    bimatoprost  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Topical
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$16.2193 - $19.3205

United States

$24.7796 - $1920.6000
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

agn-192024 | bimatoprost | bimatoprost / timolol | bimatoprostum | latisse | lumigan | prostamide | (z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((1e,3s)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-n-ethyl-5-heptenamide

Organizations (74)

Research & Development (64)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (11)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (23)

Approved Indications (3)


 

Glaucoma, Open-Angle

Hypotrichosis

Ocular Hypertension

Experimental Indications - Clinical Trial Phases 1-4 (23)


 

Alopecia (Phase 2)

Alopecia Areata (Phase 4)

Cataract (Phase 4)

Dermatology (Early Phase 1)

Eyelashes (Phase 3)

Glaucoma ()

Glaucoma, Open-Angle (Phase 4)

Graves Ophthalmopathy (Phase 4)

Hair (Phase 2)

Headache Disorders (Phase 2)

Healthy Volunteers (Phase 1)

Hypotrichosis ()

Intraocular Pressure (Phase 4)

Low Tension Glaucoma (Phase 4)

Macular Edema (Phase 4)

Migraine Disorders (Phase 2)

Nasolabial Fold (Phase 4)

Ocular Hypertension ()

Pigmentation (Phase 4)

Presbyopia (Phase 1/Phase 2)

Rhytidoplasty (Phase 4)

Uveitis, Anterior (Phase 4)

Vitiligo (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 131
  • # of Trial Organizations: 64

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue